• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $SPRC

    SciSparc Ltd.

    Subscribe to $SPRC
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. SciSparc Ltd. has an agreement with Procaps to develop and commercially manufacture SCI-110, as well as CannAmide, a palmitoylethanolamide compound in softgel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to perform a pre-clinical study for the evaluation of SCI-210 drug development program for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv, Israel.

    IPO Year:

    Exchange: NASDAQ

    Website: https://scisparc.com

    Recent Analyst Ratings for SciSparc Ltd.

    DatePrice TargetRatingAnalyst
    See more ratings

    SciSparc Ltd. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by SciSparc Ltd.

      SC 13G - SciSparc Ltd. (0001611746) (Subject)

      3/6/24 5:02:18 PM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by SciSparc Ltd.

      SC 13G - SciSparc Ltd. (0001611746) (Filed by)

      12/13/22 6:22:30 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by SciSparc Ltd. (Amendment)

      SC 13G/A - SciSparc Ltd. (0001611746) (Subject)

      5/9/22 4:08:30 PM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by SciSparc Ltd. (Amendment)

      SC 13G/A - SciSparc Ltd. (0001611746) (Subject)

      2/11/22 9:03:11 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    SciSparc Ltd. Leadership Updates

    Live Leadership Updates

    See more
    • SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP

      As part of the Company's corporate restructuring plan, Mr. Yaki Baranes will facilitate identifying new business opportunities TEL AVIV, Israel, May 30, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that as part of its restructuring plans to unlock value for shareholders, it has appointed a new Vice President of Strategy and Business Development, Mr. Yaki Baranes, to structure business strategies and facilitate identifying new business opportunities. Mr. Baranes is a business strategy expert with a

      5/30/23 8:40:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc Reinforces its New JV for Targeting Discovery with a Global Expert in the Field of Mitochondrial Transport Proteins

      JV Targets Potential Drugs for Cancers and Infectious Diseases Tel Aviv, Israel, June 15, 2022 (GLOBE NEWSWIRE) --  SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the appointment of Prof. Ciro Leonardo Pierri as special advisor for MitoCareX Bio Ltd. ("MitoCareX Bio"), SciSparc's recently established joint venture ("JV") for the discovery and development of potential drugs for cancers, infectious diseases and other life-threatening conditions. Prof. Pierri is a biochemist and serves as an associate professor at the U

      6/15/22 8:30:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prof. Avi Schroeder Joins SciSparc's Scientific Advisory Board to Support the Company's Development of SCI-160 for Treating Pain

      Prof. Schroeder to advise on SCI-160 formulation development to enhance biological effect and extended effect duration TEL AVIV, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced the appointment of Professor Avi Schroeder as a member of the Company's Scientific Advisory Board (SAB). As a member of the SAB, Prof. Schroeder will support the development of the Company's top-tier, proprietary, investigational drug candidate SCI-160 program for the treatment of pain. Prof. Schroed

      3/30/22 8:30:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    SciSparc Ltd. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

      TEL AVIV, Israel, April 25, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (NASDAQ:CMND) has led to the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia and other eating disorders. The patent application covers the use of 3-Methylmethcathinone (3-MMC) in combination with SciSparc's Palmitoylethanolamide ("PEA"). This innovative combination aims to address the complex neurobiological and psych

      4/25/25 7:59:00 AM ET
      $CMND
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

      TEL AVIV, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (NASDAQ:CMND) has led to the publication of a patent application by the South Korean Intellectual Property Office ("KIPO"). The patent application relates to a combination treatment using Clearmind's 5-methoxy-2-aminoindane ("MEAI") and SciSparc's Palmitoylethanolamide ("PEA") for the treatment of cocaine addiction. The patent is based on preclinical trial results led by P

      3/10/25 7:45:00 AM ET
      $CMND
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

      Vancouver, Canada, March 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of a patent by the Korean Intellectual Property Office (KIPO), South Korea's official patent and intellectual property authority. The patent covers the Company's innovative combination therapy of MEAI and N-Acylethanolamines for the treatment of cocaine addiction. The patent is based on preclinical trial results led by Professor Gal Yadid and his team at the Gonda Mu

      3/10/25 7:27:00 AM ET
      $CMND
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

      SciSparc will sell its MitoCareX's shares for $700,000 and exchange its remaining shares for common stock in N2OFF TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced it has signed a definitive agreement to sell its entire ownership interest in MitoCareX Bio Ltd. ("MitoCareX"), the Company's venture with Dr. Alon Silberman that focuses on drug discovery and development of cancer therapeutics by targeting the mitochondrial SLC25 protein family, to N2Off, Inc., a publicly-traded co

      3/3/25 8:25:00 AM ET
      $NITO
      $SPRC
      Agricultural Chemicals
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles

      TEL AVIV, Israel, Feb. 27, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that it has entered into a loan agreement with AutoMax Motors Ltd. ("AutoMax") to provide a $2 million loan (the "New Loan"). The funding will support AutoMax's business expansion following its entry into the direct import of Anhui Jianghuai Automobile Group Corp., Ltd. ("JAC") electric vehicles. The New Loan is in addition to previous bridge loans in an aggregate amount of $4.25 million (the "Previous Loans"). The Previous L

      2/27/25 8:45:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • N2OFF Signs Definitive Agreement to Acquire Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers

      Neve Yarak, Israel, Feb. 26, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc.\ (NASDAQ:NITO) (FSE:80W) ("N2OFF" and the "Company"), a clean tech company engaged in sustainable solutions for solar energy, energy battery storage and innovation for agri- tech, announced today that it has entered a definitive agreement to acquire MitoCareX Bio Ltd. ("MitoCareX"), a biotech company focused on drug discovery targeting cancer therapeutics, with a range of other potential diseases and disorders, through targeting the mitochondrial SLC25 protein family. N2OFF entered into a securities purchase and exchange agreement to acquire full ownership of MitoCareX from SciSparc Ltd (NASDAQ:SPRC), Dr. Alon Silberman, an

      2/26/25 9:29:00 AM ET
      $NITO
      $SPRC
      Agricultural Chemicals
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

      TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that it has reached an important settlement agreement (the "Settlement") regarding a lawsuit it filed in February 2022 with the Economic Division of the Tel Aviv-Jaffa District Court against six of the Company's former directors (the "Defendants") case number 34426-02-22 (the "Suit"). The Suit included allegations of breaches of fiduciary duties of the Defendants under the Israeli Companies Law, 1999, relating to a prior acquisit

      2/18/25 7:17:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

      TEL AVIV, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. ("Clearmind") (NASDAQ:CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has announced the publication of a patent application in Mexico for the innovative combination of 3,4-Methylenedioxymethamphetamine (MDMA)

      2/4/25 9:00:00 AM ET
      $CMND
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico

      Vancouver, Canada, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces today a patent publication by the Instituto Mexicano de la Propriedad Industrial (IMPI), the National Mexico Patent Office. The patent refers to the Company's innovative combination therapy of MEAI and N-Acylethanolamines, addressing binge behavior, including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct. The patent is part of Clearmind's successful collabora

      2/4/25 8:35:00 AM ET
      $CMND
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

      No Immediate Effect on Nasdaq Listing or Trading of the Company's Ordinary Shares TEL AVIV, Israel, Jan. 15, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced that it has received a notification letter from Nasdaq Stock Market LLC ("Nasdaq") that the Company has been granted an additional 180-day compliance period, or until July 14, 2025 to regain compliance with Nasdaq's minimum bid price rule. Nasdaq's determination is based on the Company meeting the continued listing requirement fo

      1/15/25 7:34:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    SciSparc Ltd. SEC Filings

    See more
    • Amendment: SEC Form F-4/A filed by SciSparc Ltd.

      F-4/A - SciSparc Ltd. (0001611746) (Filer)

      4/28/25 7:11:58 PM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by SciSparc Ltd.

      S-8 - SciSparc Ltd. (0001611746) (Filer)

      4/28/25 8:56:08 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by SciSparc Ltd.

      6-K - SciSparc Ltd. (0001611746) (Filer)

      4/25/25 8:19:42 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by SciSparc Ltd.

      20-F - SciSparc Ltd. (0001611746) (Filer)

      4/24/25 4:56:56 PM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by SciSparc Ltd.

      6-K - SciSparc Ltd. (0001611746) (Filer)

      4/1/25 4:00:46 PM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 425 filed by SciSparc Ltd.

      425 - SciSparc Ltd. (0001611746) (Subject)

      4/1/25 7:26:52 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by SciSparc Ltd.

      6-K - SciSparc Ltd. (0001611746) (Filer)

      4/1/25 7:21:24 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form F-3 filed by SciSparc Ltd.

      F-3 - SciSparc Ltd. (0001611746) (Filer)

      3/25/25 4:42:27 PM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form F-4/A filed by SciSparc Ltd.

      F-4/A - SciSparc Ltd. (0001611746) (Filer)

      3/11/25 6:19:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by SciSparc Ltd.

      6-K - SciSparc Ltd. (0001611746) (Filer)

      3/11/25 6:09:45 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    SciSparc Ltd. Financials

    Live finance-specific insights

    See more
    • SciSparc Adopts Limited Duration Shareholder Rights Plan

      TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its Board of Directors (the "Board") has unanimously adopted a limited duration shareholder rights plan (the "Rights Plan"), effective immediately. "Today we announced exciting positive results from our weight loss and metabolic disorder program with our proprietary psychedelic-based treatment," said Oz Adler, SciSparc's Chief Executive Officer. "Unfortunately, SciSparc, like many other clinical-stag

      11/28/23 8:55:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel

      SciSparc seeks to scale up revenues and will consider transferring its pharmaceutical activities to a separate legal entity and exploring the possibility of dividend distribution TEL AVIV, Israel, Nov. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the signing of a non-binding letter of intent to merge with a leading vehicle importer company in Israel (the "Target Company"). This merger (the "Merger) is expected to be consummated by means of a reverse triangular merger, pursua

      11/22/23 7:42:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split

      Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and outstanding TEL AVIV, Israel, Sept. 27, 2023 (GLOBE NEWSWIRE) --  SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announces today that its previously announced reverse share split of its issued and outstanding ordinary shares, no par value at a ratio of 1-for-26, is expected to be implemented after market close today. The Company's Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-split basis at

      9/27/23 7:58:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SciSparc's Board of Directors Provides Strategic Decision

      TEL AVIV, Israel, June 09, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced that the Company's board of directors resolved to initiate a process to review potential strategic transactions with the goal of maximizing shareholder value. Potential strategic transactions to be explored and evaluated during the review process may include additional investments in innovative companies, acquisitions, a strategic partnership with one or more parties, or the licensing of one or more of the Company's pr

      6/9/22 8:30:00 AM ET
      $SPRC
      Biotechnology: Pharmaceutical Preparations
      Health Care